The Best Reseller Hosting Suppliers in August Released by Leading Review SiteTop10BestSEOHosting.com Sep 1, 2014 07:05PM

(PRWEB) September 02, 2014

Top10BestSEOHosting.com is a leading review website in the world. It has recently compared many top web hosting companies and announced that GreenGeeks, Arvixe and Hostgator are the best reseller hosting suppliers in August.

GreenGeeks (http://www.greengeeks.com/cgi-bin/affiliates/clickthru.cgi?id=seohosts) is one of the best web hosting companies from the USA. The company has a lot of useful products for sale. On its website, customers can always get great products at low rates.

As one of the Top 10 Web Hosting in 2014, Arvixe is a popular supplier of cheap web hosting, and it offers rich features and great Windows hosting solutions at affordable rates. It is well-known for its quality services at affordable prices and has been awarded as one of the fastest hosting providers in the whole world.

Hostgator is a web hosting provider and a privately held liability corporation. It is offering hosting services for a range of websites, from personal pages to enterprise websites (with specific plans for each category).

According to the IT manager of Top10BestSEOHosting.com, reseller hosting is a very popular way for webmasters to make money from hosting. The account owner is allowed to use the allotted resources to host others' websites under his name, brand or company.

Top10BestSEOHosting.com
Top10BestSEOHosting.com is an independent, advertising-supported hosting comparison service provider. Its experts have been evaluating hosting companies for many years. It wants to offer more useful information for clients who want to find the most suitable hosting products in an easy way.

Top10BestSEOHosting.com aims to provide people with better products at cost-effective prices. For more details, please visit: http://www.top10bestseohosting.com/best-reseller-hosting/.

Read the full story at http://www.prweb.com/releases/2014/09/prweb12134569.htm


MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) Sep 1, 2014 07:00PM

LA JOLLA, Calif., Sept. 1, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it will present at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) to be held this September in Mont Tremblant, Quebec, Canada. In June 2014, MediciNova announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis in an animal model. The presentation, "MN-001 (tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the Bleomycin-induced idiopathic pulmonary fibrosis mouse model," scheduled for the afternoon of September 23, 2014, will extend understanding about the mechanism by which MN-001 improves pathology in idiopathic pulmonary fibrosis (IPF), for which there is a large unmet medical need.

About MN-001

MN-001 is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) 3 and 4, and inhibition of 5-lipoxygenase (5-LO). It is postulated that inhibition of the 5-LO pathway exerts anti-inflammatory actions, which has implications in various inflammatory diseases such as arthritis, osteoarthritis, and allergy. Recently, 5-LO has been postulated as a pathogenic factor in fibrotic changes. MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis.

Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

About Bleomycin-induced Pulmonary Fibrosis Model

Bleomycin is an anti-cancer drug used for treatment of different types of malignant tumors. One of the known side effects of Bleomycin treatment is pulmonary fibrosis. Bleomycin-induced pulmonary fibrosis in the mouse is widely used as an animal model for the study of pulmonary fibrosis.

About Pulmonary Fibrosis

Pulmonary fibrosis (PF) is a progressive disease characterized by scarring of the lungs that thickens the lining, causing an irreversible loss of the tissue's ability to transport oxygen. The causes of PF are variable such as anti-cancer drug therapy or exposure to chemicals. Idiopathic Pulmonary Fibrosis (IPF) is one type of PF without a clear cause. According to the Coalition for Pulmonary Fibrosis, IPF affects approximately 128,000 individuals in the U.S., with about 48,000 new cases diagnosed annually. The prognosis for IPF is poor and about two-thirds of affected patients die within five years of diagnosis. There are no pharmaceutical treatments currently approved for IPF in the U.S.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) or opioid addictions, MN-221 for the treatment of acute exacerbations of asthma and MN-001 for NASH and IPF. MN-166 is being developed for the treatment of multiple indications, largely through investigator-sponsored trials and outside funding. MediciNova is engaged in strategic partnering and consortium funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-001, MN-166 and MN-221. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-001, MN-166 and MN-221 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2013 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

CONTACT: INVESTOR CONTACT:
         Geoff O'Brien
         Vice President
         MediciNova, Inc.
         info@medicinova.com

Source: MediciNova, Inc.


MediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) Sep 1, 2014 07:00PM

LA JOLLA, Calif., Sept. 1, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it will present at the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF) to be held this September in Mont Tremblant, Quebec, Canada. In June 2014, MediciNova announced positive results from a study that examined the potential clinical efficacy of MN-001 (tipelukast) for the treatment of pulmonary fibrosis in an animal model. The presentation, "MN-001 (tipelukast), a nonselective phosphodiesterase, 5-lipoxygenase, leukotriene, phospholipase C and thromboxane A2 inhibitor, demonstrates anti-fibrotic effects in the Bleomycin-induced idiopathic pulmonary fibrosis mouse model," scheduled for the afternoon of September 23, 2014, will extend understanding about the mechanism by which MN-001 improves pathology in idiopathic pulmonary fibrosis (IPF), for which there is a large unmet medical need.

About MN-001

MN-001 is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterase (PDE) 3 and 4, and inhibition of 5-lipoxygenase (5-LO). It is postulated that inhibition of the 5-LO pathway exerts anti-inflammatory actions, which has implications in various inflammatory diseases such as arthritis, osteoarthritis, and allergy. Recently, 5-LO has been postulated as a pathogenic factor in fibrotic changes. MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis.

Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and considered generally safe and well-tolerated.

About Bleomycin-induced Pulmonary Fibrosis Model

Bleomycin is an anti-cancer drug used for treatment of different types of malignant tumors. One of the known side effects of Bleomycin treatment is pulmonary fibrosis. Bleomycin-induced pulmonary fibrosis in the mouse is widely used as an animal model for the study of pulmonary fibrosis.

About Pulmonary Fibrosis

Pulmonary fibrosis (PF) is a progressive disease characterized by scarring of the lungs that thickens the lining, causing an irreversible loss of the tissue's ability to transport oxygen. The causes of PF are variable such as anti-cancer drug therapy or exposure to chemicals. Idiopathic Pulmonary Fibrosis (IPF) is one type of PF without a clear cause. According to the Coalition for Pulmonary Fibrosis, IPF affects approximately 128,000 individuals in the U.S., with about 48,000 new cases diagnosed annually. The prognosis for IPF is poor and about two-thirds of affected patients die within five years of diagnosis. There are no pharmaceutical treatments currently approved for IPF in the U.S.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS) or opioid addictions, MN-221 for the treatment of acute exacerbations of asthma and MN-001 for NASH and IPF. MN-166 is being developed for the treatment of multiple indications, largely through investigator-sponsored trials and outside funding. MediciNova is engaged in strategic partnering and consortium funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-001, MN-166 and MN-221. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-001, MN-166 and MN-221 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2013 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

CONTACT: INVESTOR CONTACT:
         Geoff O'Brien
         Vice President
         MediciNova, Inc.
         info@medicinova.com

Source: MediciNova, Inc.


New School Year, Time for a Bullying Alert with NoBullying Sep 1, 2014 06:30PM

London, UK (PRWEB) September 01, 2014

The new school year is upon us and for every parent a new school year could also mean brushing back in with school bullying. It is time for parents and educators to understand what bullying could lead to for children before it is too late, all with NoBullying's guide to school bullying this year, released today.

It is first to be noted that bullying is not mere teasing or "kids' play." Especially if the child is new at school, bullies are, sadly, everywhere and they have various methods of bullying to intimidate and push down other children.

The bullies' actions may start out as simple teasing, but over time verbal harassment can lead to physical harm. This alone can have severe consequences for both the bully and the target.

Even if it is verbal, bullying is an expression of violence in its purest form. Bullying can progress to being physical, thus harming the bully, the victim and the bystanders involved.

But what could the acts of bullying lead to? Bullying could often lead to a variety of symptoms and actions for the bully and the victim.

Children who are victims of bullying are inflicted by violence in a physical sense that is done subtly by the bully to escape punishment from teachers. Some children at school could face hitting, tripping, pushing, slapping, or even their belongings destroyed. If a child is coming home with unexplained injuries, damaged clothing or lost/damaged possessions or even any signs of stress, parents need to step in right away.

Those who are present when a bully is causing harm to his or her intended target may also be affected by what is witnessed. Bystanders may be affected by what they see or hear, which could have long lasting psychological consequences, even as adults. Children who witness the bullying of their friends are most likely to experiment with smoking, drugs, alcohol or delve into promiscuous activities, even leading in some cases to teenage pregnancy.

It may not seem directly related but bullying and acts of unkindness could have serious consequences on a child's or teen's ability to make correct decisions. They may delve into these things to get on the good side of the bully, including running away from home.

It is also to be highlighted that more than 3.2 million students fall victim to bullying every year and that one in four teachers do nothing because they see there is nothing wrong with bullying. This is a serious call for parents to take note of bullying in school and learn how to stand up to it properly.

Ciaran Connolly, Co-Founder of NoBullying.com, said, "With the new school year upon us, we need to keep fighting bullying in school. It takes the entire community to end bullying in school."

He added that parents and teachers should make a point to educate the younger generations about the sad outcome of bullying online and offline. According to Connolly, it is quite imperative to press for more firm laws condemning all acts of bullying and harassment.

NoBullying.com features many pages dedicated to parents, teens, teachers, health professionals as well as posts related to cyber safety and the latest news about law making concerning curbing Bullying worldwide as well as inspirational Bullying Poems and famous Bullying Quotes.

The website regularly updates its bullying statistics and cyber bullying statistics as it is essential to understand how widespread the bullying epidemic is. It also regularly runs cyber bullying surveys and questionnaires to get recent updated statistics on everything related to cyberbullying.

He also added that anyone suffering from bullying in any form or way can always find advice and help on the NoBullying website – but if anyone is suffering from severe bullying or cyber bullying, the best thing is to talk to someone locally – a parent, teacher or local organization that has been set up to help with specialized councilors to deal with this topic.

Read the full story at http://www.prweb.com/releases/2014/09/prweb12135443.htm


Solution Designed Specifically for Med/Surg Floors Addresses Unmet Patient Surveillance Needs, Provides Innovative Solutions to Assist with Hospital and Aged-Care Accreditation Sep 1, 2014 06:30PM

The Welch Allyn Connex® Clinical Surveillance System (CSS) integrates technology from Masimo, Covidien and EarlySense to aid in the early detection of patient deterioration, and to help reduce patient falls and pressure injuries. It provides cost-effective solutions to assist with compliance for the following NSQHS National Quality Standards:

Standard No. 8.  Preventing and Managing Pressure Injuries

Standard No. 9.  Recognising and Responding to Clinical Deterioration in Acute Health Care

Standard No. 10. Preventing Falls and Harm from Falls

RYDALMERE, Australia--(BUSINESS WIRE)-- Welch Allyn, a leading medical diagnostic device company that delivers pragmatic innovation at the point of care, today introduced the industry's most comprehensive clinical surveillance system designed specifically for the medical/surgical (med/surg) environment. Enabled through a unique set of medical device partnerships, this solution expands the capabilities of traditional intermittent vital signs systems providing effective tools for the clinical staff on med/surg floors to help them monitor and identify early warning signs of potential patient deterioration and enhance patient safety.

Now available in Australia and New Zealand, the Welch Allyn Connex® Clinical Surveillance System is the centerpiece of the company's objective to optimise care on med/surg floors by enabling proactive, cost-effective care to beds outside the intensive care unit (ICU). Building upon Welch Allyn's market leadership position in vital signs systems, the Connex CSS is designed to electronically capture and document vitals from the bedside directly to the electronic medical record (EMR) and alert clinicians to the risk of significant adverse events that may occur in hospitals, including issues around failure to rescue, respiratory failure, falls, hospital-acquired pressure ulcers, and cardiopulmonary arrests.

The Connex CSS system benefits from the integration of three additional monitoring parameters—all designed to help in avoiding adverse events—into the Welch Allyn Connex® Vital Signs Monitor (CVSM) in addition to traditional automated measurements such as pulse rate, blood pressure, temperature and pulse oximetry. The Connex® CSS solution offers acoustic respiration from Masimo (NASDAQ: MASI); Microstream® end-tidal carbon dioxide technology from Covidien (NYSE: COV); and contact-free motion, heart rate and respiratory rate monitoring from EarlySense.

The system can also include an optional central station for remote viewing of patient status and alarm notification capabilities to deliver critical patient alarms where and when staff need them. The solution leverages Welch Allyn's extensive EMR partnerships to enable connectivity and increase access to accurate patient information. In conjunction with the launch of the Connex CSS, the company has also introduced the Connex® Service Dashboard which provides easy access to equipment status and helps facilitate management of technology.

The majority of patients in an acute care hospital are cared for in med/surg units. Patients within med/surg units span a wide range of age, complexity, acuity and disease state. Due to their size and scope, med/surg units can be operationally challenging to manage. Today, clinicians on med/surg units must manage the admission, discharge and care for many clinically complex patients throughout a typical workday, at a far lower nurse-to-patient ratio than in higher acuity environments.

The Connex CSS has already enabled Meadville Medical Center in Meadville, Pennsylvania (USA) to better detect and respond to the onset of patient respiratory deterioration following surgery. Says Kimberlie Bovard, MSN, RN, and nursing informatics specialist with Meadville, “post-surgical patients receiving pain medication, or suffering from respiratory co-morbidities can present a higher risk for respiratory deterioration and life-threatening events. We needed a solution that would be easy to deploy on med/surg floors, in addition to our existing vital signs interfaces for our EMR system, and complement our nursing staff workflows and skill sets.”

Orange Heath Service (Australia, NSW) is currently evaluating the EarlySense system in the medical ward. Dr. John Lambert is leading the project with results expected later this month.

About Welch Allyn

Welch Allyn helps reduce risk and improve patient safety, satisfaction and outcomes in a variety of clinical settings through a complete range of EMR-interfaced vital signs and cardiac monitoring diagnostic solutions, physical diagnosis instruments and infection-control products. The company specializes in helping doctors, nurses and other frontline providers across the globe streamline workflow by developing innovative solutions that enable immediate access to accurate patient data. A leading global healthcare company founded in 1915 and headquartered in Skaneateles Falls, N.Y. (USA), Welch Allyn is a family-owned business that employs over 2,600 employees in 26 different countries. More information about Welch Allyn and its complete line of connected products and solutions may be found at www.welchallyn.com. Like us on Facebook and follow us on Twitter.

About Masimo

Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve “unsolvable” problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry’s ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb® ), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), in addition to measure-through motion SpO2, and pulse rate. In 2009, Masimo introduced rainbow® Acoustic Monitoring™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET® and Masimo rainbow® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of “Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications®.” Additional information about Masimo and its products may be found at www.masimo.com.

About Covidien

Covidien has a long history in respiratory care and decades of experience in such areas as patient monitoring, ventilation and airway management. Covidien Respiratory and Monitoring Solutions is committed to taking a comprehensive approach to developing innovative products and improving outcomes in respiratory care by focusing on three key areas: patient safety, medical efficacy and healthcare efficiency. Covidien offers a suite of industry-leading monitoring technologies, including Microstream® capnography that provide clinicians with critical patient information enabling them to make patient-care decisions quickly and effectively. For additional information please visit www.covidien.com/rms.

About EarlySense

EarlySense has brought to market an innovative technology designed to advance proactive patient care and enable clinicians to achieve better patient outcomes, by assisting in preventing adverse events from occurring. The company’s flagship product, the EarlySense System, is a continuous, contact-free, patient monitoring solution that monitors and documents a patient’s vital signs and movement using a sensor that is placed underneath a bed mattress. There are no leads or cuffs to connect to the patient who has complete freedom of movement and is not burdened by any cumbersome attachments. The system is designed to monitor non-ICU ‘lower risk’ patients on medical surgical floors who are usually monitored by nursing staff approximately once every four hours. The system is currently installed at hospitals and rehabilitation centers in the USA and Europe. It is also commercially available in Canada. EarlySense Inc. is headquartered in Waltham, MA. For additional information, please visit www.earlysense.com. Follow us on Twitter and like us on Facebook.

Welch Allyn

Jamie Arnold, APR

Public Relations Manager

+1-315-685-4599

jamie.arnold@welchallyn.com

Source: Welch Allyn


More Press Releases

View Older Stories

Sep 1, 2014 06:03PM Los Angeles Hotel Operators Express Concern Over Contrary Wage Proposals
Sep 1, 2014 06:01PM Research Finds That Small Dogs Can't Go Without Their Toothbrushes
Sep 1, 2014 06:00PM ESCORT Schedules Major News Webcast
Sep 1, 2014 06:00PM Exelixis Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Sep 1, 2014 06:00PM FormFactor, Inc. Raises Third Quarter Guidance Range
Sep 1, 2014 05:10PM US strong, rest of the world riding the bear says LJM Developments CEO
Sep 1, 2014 05:00PM Spring Has Sprung With Horseland's Spring 2014 Catalogue, Featuring New Products For Equine Enthusiasts
Sep 1, 2014 04:30PM Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference
Sep 1, 2014 04:30PM MGM Resorts International President To Present At The Mizuho Investment Conference In Tokyo
Sep 1, 2014 04:20PM Announcement: GuitarControl.com releases "Guitar Lesson on Creating Blues Licks - How to Create Pentatonic Licks"
Sep 1, 2014 04:16PM Partners Real Estate Investment Trust Provides Holyrood Transaction Update and Property Sale Update
Sep 1, 2014 04:10PM Announcement: GuitarControl.com releases "Lead Guitar Lesson on Pentatonic Scale - Pentatonic Scale Shapes"
Sep 1, 2014 03:30PM September 3: Start Your New Career with MAU at Magna!
Sep 1, 2014 03:05PM Ekwestrel Corp Reports October Pump Systems Optimization Course Concerns 40% Average Efficiency
Sep 1, 2014 03:00PM Thomas Exchange Global Offers Best Currency Exchange Rates to Travellers of Turkey this autumn
Sep 1, 2014 03:00PM Orbital Travel The Nile Cruise Specialist Announce 5 Star Nile River Cruise Offer
Sep 1, 2014 03:00PM eReflect Introduces Cloud Computing Infrastructure To Readers Of The Ultimate Spelling Blog
Sep 1, 2014 02:42PM New Clinical Trial Results Demonstrate Importance of St. Jude Medical Fractional Flow Reserve in Guiding Treatment of NSTEMI Patients
Sep 1, 2014 02:00PM CGTrader.com Targets Design Visionaries to Create the Future Supercar
Sep 1, 2014 02:00PM Introducing GeckoEye: Security for Peace of Mind
Sep 1, 2014 01:30PM Sale of CNH Industrial's stock grant shares
Sep 1, 2014 01:25PM No Medical Exam Life Insurance Plans Can Cover Funeral Expenses
Sep 1, 2014 01:18PM TSL Education Renames as TES Global
Sep 1, 2014 01:15PM No Medical Exam Life Insurance Plans Can Be Purchased at Affordable Rates
Sep 1, 2014 01:00PM KVCHosting is Named as the Best VPS SSD 2014 Host by ssdhostingreview.com
Sep 1, 2014 01:00PM KVCHosting Announces Labor Day Promotion
Sep 1, 2014 01:00PM No Medical Exam Life Insurance - Clients Can Find Affordable Quotes at Lifeinsurancebroker.us
Sep 1, 2014 01:00PM Sunrise Reputation Announces New Reputation Management Services Specifically Designed for Union Representatives
Sep 1, 2014 12:00PM Applications for the Subjects of the "Precious Metals Research Grants" of Up to 5 Million Yen Open on September 1
Sep 1, 2014 01:00PM PrimeSport Announces "PrimeSport Ticket Tuesdays" Where Fans Can Win Tickets to NFL Games
Sep 1, 2014 12:45PM Female Hormonal Imbalances - Can't Seem to Shed Those Extra Pounds? Discussion with Medical Expert Dr. Clairborne on Dr. Carol Francis Talk Radio Today
Sep 1, 2014 12:35PM Portable One Now Offering Major Brand Custom Laptops at Cost-effective Prices
Sep 1, 2014 12:30PM North America Commercial Aviation Aircraft Lighting Market is Expected to Reach $901.14 million in 2019 - New Report by MicroMarket Monitor
Sep 1, 2014 12:27PM Ontario doesn't need more wind power
Sep 1, 2014 12:27PM Ontario doesn't need more wind power
Sep 1, 2014 12:25PM Clients Can Use Life Insurance As Collateral for Loans!
Sep 1, 2014 12:10PM Compare Online Life Insurance Quotes and Find the Best Rates Online
Sep 1, 2014 12:05PM Record Number of Businesses from across Europe Seek Recognition in Awards
Sep 1, 2014 12:02PM North America Food & Beverage Stabilizers & Systems Market is Expected to Reach $2,557.9 million in 2018 - New Report by MicroMarket Monitor
Sep 1, 2014 12:02PM Osborne Clarke hires Cristine Brinkman as a Partner in the Amsterdam office
Sep 1, 2014 12:00PM Commercial Movers in Los Angeles Can Help Business Owners Save Money When Moving
Sep 1, 2014 11:50AM Hosting1000.net Releases List for Best VPS Hosting Providers 2014
Sep 1, 2014 11:48AM Canada's Building Trades Unions Celebrate Labour Day with the Launch of NEW Website
Sep 1, 2014 11:30AM North America Solar Photovoltaic (PV) Market is Expected to Reach $5778.94 million in 2018 - New Report by MicroMarket Monitor
Sep 1, 2014 11:30AM Europe Soy Protein Market is Expected to Reach $2,069.8 million in 2018 - New Report by MicroMarket Monitor
Sep 1, 2014 11:15AM North American Chromatography Systems Market is Expected to Reach $2669.0 million in 2018 - New Report by MicroMarket Monitor
Sep 1, 2014 11:10AM Traveling Back to the Wild West with "Chains"
Sep 1, 2014 11:00AM Debt Consolidation USA Shares Financial Effects Of Job Security
Sep 1, 2014 11:00AM Telematics West Coast to Unite the Rapidly Growing West Coast Connected Car Community
Sep 1, 2014 11:00AM Queens Bankruptcy Attorney Bruce Feinstein, Esq. Warns About the Dangers of Payday Loans
View Older Stories